Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate.

Jørgensen J, Kefalas P.

J Mark Access Health Policy. 2019 Jun 27;7(1):1635842. doi: 10.1080/20016689.2019.1635842. eCollection 2019.

2.

Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching.

Jørgensen J, Mungapen L, Kefalas P.

J Mark Access Health Policy. 2019 Feb 4;7(1):1573164. doi: 10.1080/20016689.2019.1573164. eCollection 2019.

3.

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.

Jørgensen J, Servos S, Kefalas P.

J Mark Access Health Policy. 2018 Aug 6;6(1):1500419. doi: 10.1080/20016689.2018.1500419. eCollection 2018.

4.

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.

Kefalas P, Ali O, Jørgensen J, Merryfield N, Richardson T, Meads A, Mungapen L, Durdy M.

J Mark Access Health Policy. 2018 Aug 20;6(1):1511679. doi: 10.1080/20016689.2018.1511679. eCollection 2018.

5.

Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.

Jørgensen J, Kefalas P.

J Mark Access Health Policy. 2017 Jul 31;5(1):1355203. doi: 10.1080/20016689.2017.1355203. eCollection 2017.

6.

Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.

Driscoll D, Farnia S, Kefalas P, Maziarz RT.

Stem Cells Transl Med. 2017 Aug;6(8):1723-1729. doi: 10.1002/sctm.16-0487. Review.

7.

A price comparison of recently launched proprietary pharmaceuticals in the UK and the US.

Jørgensen J, Kefalas P.

J Mark Access Health Policy. 2016 Sep 12;4. doi: 10.3402/jmahp.v4.32754. eCollection 2016.

8.

Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion.

Bradshaw SE, Gala S, Nanavaty M, Shah A, Mwamburi M, Kefalas P.

BMC Ophthalmol. 2016 Jul 11;16:104. doi: 10.1186/s12886-016-0282-5. Review.

9.

Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom.

Weidlich D, Kefalas P, Guest JF.

Transfusion. 2016 May;56(5):1038-45. doi: 10.1111/trf.13513. Epub 2016 Apr 4. Review.

PMID:
27041389
10.

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.

Bubela T, McCabe C, Archibald P, Atkins H, Bradshaw SE, Kefalas P, Mujoomdar M, Packer C, Piret J, Raxworthy M, Soares M, Viswanathan S.

Regen Med. 2015;10(7):897-911. doi: 10.2217/rme.15.51. Epub 2015 Nov 13. Review.

11.

Cell-based therapy technology classifications and translational challenges.

Mount NM, Ward SJ, Kefalas P, Hyllner J.

Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20150017. doi: 10.1098/rstb.2015.0017. Review.

12.

Market access pathways for cell therapies in France.

Rémuzat C, Toumi M, Jørgensen J, Kefalas P.

J Mark Access Health Policy. 2015 Nov 18;3. doi: 10.3402/jmahp.v3.29094. eCollection 2015.

13.

Reimbursement of licensed cell and gene therapies across the major European healthcare markets.

Jørgensen J, Kefalas P.

J Mark Access Health Policy. 2015 Sep 30;3. doi: 10.3402/jmahp.v3.29321. eCollection 2015.

14.

Efficient diterpene production in yeast by engineering Erg20p into a geranylgeranyl diphosphate synthase.

Ignea C, Trikka FA, Nikolaidis AK, Georgantea P, Ioannou E, Loupassaki S, Kefalas P, Kanellis AK, Roussis V, Makris AM, Kampranis SC.

Metab Eng. 2015 Jan;27:65-75. doi: 10.1016/j.ymben.2014.10.008. Epub 2014 Nov 7.

PMID:
25446975
15.

Evaluation of anti-oxidant and acetylcholinesterase activity and identification of polyphenolics of the invasive weed Dittrichia viscosa.

Trimech I, Weiss EK, Chedea VS, Marin D, Detsi A, Ioannou E, Roussis V, Kefalas P.

Phytochem Anal. 2014 Sep-Oct;25(5):421-8. doi: 10.1002/pca.2510. Epub 2014 Apr 14.

PMID:
24733603
16.

Origanum species native to the island of Crete: in vitro antioxidant characteristics and liquid chromatography-mass spectrometry identification of major polyphenolic components.

Tair A, Weiss EK, Palade LM, Loupassaki S, Makris DP, Ioannou E, Roussis V, Kefalas P.

Nat Prod Res. 2014;28(16):1284-7. doi: 10.1080/14786419.2014.896011. Epub 2014 Mar 18.

PMID:
24635145
17.

Phenolic profiles and antioxidant and anticarcinogenic activities of Greek herbal infusions; balancing delight and chemoprevention?

Kaliora AC, Kogiannou DA, Kefalas P, Papassideri IS, Kalogeropoulos N.

Food Chem. 2014 Jan 1;142:233-41. doi: 10.1016/j.foodchem.2013.07.056. Epub 2013 Jul 19.

PMID:
24001836
18.

Modulation of the antioxidant/pro-oxidant balance, cytotoxicity and antiviral actions of grape seed extracts.

Ignea C, Dorobanţu CM, Mintoff CP, Branza-Nichita N, Ladomery MR, Kefalas P, Chedea VS.

Food Chem. 2013 Dec 15;141(4):3967-76. doi: 10.1016/j.foodchem.2013.06.094. Epub 2013 Jun 29.

PMID:
23993573
19.

Herbal infusions; their phenolic profile, antioxidant and anti-inflammatory effects in HT29 and PC3 cells.

Kogiannou DA, Kalogeropoulos N, Kefalas P, Polissiou MG, Kaliora AC.

Food Chem Toxicol. 2013 Nov;61:152-9. doi: 10.1016/j.fct.2013.05.027. Epub 2013 May 24.

PMID:
23712099
20.

o-Quinone involvement in the prooxidant tendency of a mixture of quercetin and caffeic acid.

Chedea VS, Choueiri L, Jisaka M, Kefalas P.

Food Chem. 2012 Dec 1;135(3):1999-2004. doi: 10.1016/j.foodchem.2012.06.094. Epub 2012 Jul 3.

PMID:
22953950

Supplemental Content

Loading ...
Support Center